tbuckley/cabot-search huggingface dataset:
Expression and immunogenicity of the cancer-testis antigen CT7 (MAGE-C1) in patients with multiple myeloma
Authors: A. Curioni Fontecedro, A. J. Knights, M. Tinguely, O. de la Rosa, B. Lopes, H. Moch, C. Renner, A. Zippelius, A. Knuth
Journal: Journal of Clinical Oncology (2007)

8112 Introduction: CT7 (MAGE-C1) is an antigen with restricted expression in cancer and testis (CT antigen). It has been demonstrated to be expressed in more than 55% of Multiple Myeloma (MM) bone marrow biopsies (BMB). CT7 immunogenicity was so far unknown. Thus we aimed to analyse the immune response of MM patients towards CT7. Moreover, we evaluated correlations between CT7 expression and prognostic features. Methods: The CT7 gene was cloned from a MM cell line by RT-PCR; the protein has been expressed in E. coli, purified by affinity FPLC and analysed by Mass Spectrometry. MM patients’ sera (1:200 dilution) were analysed towards the CT7 full length protein by Western Blot (WB) and against truncated CT7 by WB and ELISA. BMB were analyzed by immunohistochemistry (IC) for CT7 expression and for proliferation/differentiation markers. Specific chromosomal aberrations were investigated by FISH analysis. Results: Both full-length and truncated proteins have been produced and fully sequenced. Out of 55 patients’ sera 12 typed positive for the full length protein by WB analysis. Ten of sixteen (62.5%) BMB were positive for CT7. So far no correlation with prognostic features was established. Conclusions: For the first time the in vivo immunogenicity of CT7 was demonstrated. Our preliminary data indicate that spontaneous anti-CT7 humoral responses occur in a significant proportion of MM patients. All detectable humoral responses observed to date are in patients with advanced disease. Characterization of antibody-binding sites and specific CD8/CD4 T cell responses in MM patients is on-going. Our data support the broad and strong expression of CT7 in patients with MM. To date CT7 represent the most immunogenic cancer testis antigen in MM. No significant financial relationships to disclose.
TCT-586 Comparison of second-generation with first-generation drug eluting stent for coronary chronic total occlusion intervention
Authors: Min Soo Cho, Cheol Hyun Lee, Yu Na Kim, Jae Seok Bae, Pil Hyung Lee, Jae-Hyung Roh, Mineok Chang, Sung-Han Yoon, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2015)
TCT-581 Impact of Vessel Size on Clinical Outcomes of Revascularization With Biolimus A9TM-Eluting Stent in Patients with Acute Coronary Syndrome
Authors: Guang-Won Seo, Ho-Chul Shin, Pil Sang Song, Dong-Kie Kim, Ki-Hun Kim, Sang-Hoon Seol, Han-Young Jin, Tae-Hyun Yang, Jeong-Sook Seo, Doo-Il Kim
Journal: Journal of the American College of Cardiology (2015)
GW27-e0168 Efficacy and safety of fixed-dose combination of irbesartan/atorvastatin in patients with hypercholesterolemia and hypertension
Authors: Sang-Hyun Kim, Hyang-Lim Lee, Hack-Lyoung Kim, Woo-Hyun Lim, Jae-Bin Seo, Woo-Young Chung, Joo-Hee Zo, Myung-A Kim
Journal: Journal of the American College of Cardiology (2016)
TCT-593 Gender Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From TWENTE and DUTCH PEERS
Authors: Marlies M. Kok, Liefke C. van der Heijden, Hanim Sen, Marije M. Löwik, Rutger Anthonio, Hans W. Louwerenburg, Frits H. de Man, Gerard C. Linssen, Maarten J. Ijzerman, Carine J. Doggen, Angela H. Maas, Roxana Mehran, Clemens von Birgelen
Journal: Journal of the American College of Cardiology (2015)
TCT-518 Diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: Clinical outcomes of a subgroup analysis from an all-comers absorb registry
Authors: Santiago J. Camacho Freire, Jessica Roa-Garrido, Antonio Gomez Menchero, Rosa M. Cardenal, Javier Leon Jimenez, Prudencia Gomez Fernandez, Francisco J. Landero Garcia, Jose F. Diaz Fernandez
Journal: Journal of the American College of Cardiology (2015)
TCT-231 Exenatide Does Not Improve Myocardial Salvage In Patients With An Acute Myocardial Infarction Successfully Treated With Primary Percutaneous Coronary Intervention: The First Results Of The EXAMI Trial
Authors: Sebastiaan Roos, Leo Timmers, Geert P. van Hout, Paul S. Biesbroek, Robin Nijveldt, Birgitta Velthuis, Michiel Voskuil, Pieter R. Stella, Pieter Doevendans, Niels van Royen, Albert C. van Rossum, Otto Kamp, Yolande Appelman
Journal: Journal of the American College of Cardiology (2015)
TCT-12 Impact of overlap on long-term clinical outcomes in patients undergoing everolimus-eluting bioresorbable vascular scaffolds implantation in routine clinical practice: insights from the European multicenter GHOST-EU registry
Authors: Luis Ortega-Paz, Giuseppe Giacchi, Salvatore Brugaletta, Manel Sabate, Davide Capodanno, Tommaso Gori, Holger Nef, Azeem Latib, Julinda Mehilli, Maciej Lesiak, Giuseppe Caramanno, Christoph Naber, Carlo Di Mario, Antonio Colombo, Piera Capranzano, Jens Wiebe, Aleksander Araszkiewicz, Salvatore Geraci, Stylianos A. Pyxaras, Alessio Mattesini, Toru Naganuma, Thomas Munzel, Corrado Tamburino
Journal: Journal of the American College of Cardiology (2015)
Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea
Authors: J. Serrano‐Pariente, V. Plaza, J. B. Soriano, M. Mayos, A. López‐Viña, C. Picado, L. Vigil
Journal: Allergy (2016)

Abstract Background Continuous positive airway pressure ( CPAP ) in asthma patients with concomitant obstructive sleep apnea syndrome ( OSAS ) seems to have a favorable impact on asthma, but data are inconsistent due to methodological limitations of previous studies. Methods Prospective, multicenter study. We examined asthma outcomes after 6 months of CPAP in 99 adult asthma patients (mean age 57 years) with OSAS (respiratory disturbance index ≥20). Asthma control and quality of life were assessed with the Asthma Control Questionnaire ( ACQ ) and the Mini Asthma Quality of Life Questionnaire (Mini AQLQ ), respectively. Data were analyzed by intention‐to‐treat basis. Results The mean ± SD score of the ACQ decreased from 1.39 ± 0.91 at baseline to 1.0 ± 0.78 at 6 months ( P = 0.003), the percentage of patients with uncontrolled asthma from 41.4% to 17.2% ( P = 0.006), and the percentage of patients with asthma attacks in the 6 months before and after treatment from 35.4% to 17.2% ( P = 0.015). The score of the mAQLQ increased from 5.12 ± 1.38 to 5.63 ± 1.17 ( P = 0.009). There were also significant improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversibility, and exhaled nitric oxide values (all P &lt; 0.05). No significant changes were observed in drug therapy for asthma or their comorbidities nor in the patients’ weight. Conclusions Asthma control (both actual and future risk), quality of life, and lung function improved after starting continuous positive airway pressure in asthmatics with moderate to severe obstructive sleep apnea syndrome.
Cross-Reactive TH1 Cells to Aspergillus Fumigatus and Candida Albicans
Authors: Claudia Stuehler, Nina Khanna, Silvia Bozza, Teresa Zelante, Michaela Kruhm, Sarah Lurati, Barbara Conrad, Eike Kallmeyer, Sven Krappmann, Hermann Einsele, Jean-Paul Latge, Juergen Loeffler, Luigina Romani, Max S Topp
Journal: Blood (2010)
GW27-e0686 Lowering of mean resting heart rate is associated with less cardiovascular events in bisoprolol-treated Asian patients with coronary artery disease: results from a multinational, observational study
Authors: Chen Yundai, Vinh Nguyen Pham, Shian Huang, Dongsoo Kim, Tianrong Ma, Xinchun Yang, Yundai Chen
Journal: Journal of the American College of Cardiology (2016)
TCT-523 Percutaneous Coronary Intervention For Chronic Total Coronary Artery Occlusion With The Implantation Of Bioresorbable Everolimus-Eluting Scaffolds: Poznan CTO-Absorb Pilot Registry
Authors: Maciej Lesiak, Magdalena Lanocha, Aleksander Araszkiewicz, Andrzej Siniawski, Marek Grygier, Anna Olasinska-Wisniewska, Sylwia Iwanczyk, Malgorzata Pyda, Wlodzimierz Skorupski, Przemyslaw Mitkowski, Michal B. Lesiak, Stefan Grajek
Journal: Journal of the American College of Cardiology (2015)
Use of cyanoacrylate to treat mucosal perforations during or after peroral endoscopic myotomy
Authors: Oscar Hernández-Mondragón, Omar Solórzano-Pineda, Gerardo Blanco-Velasco, Juan Blancas-Valencia
Journal: Endoscopy (2016)

Peroral endoscopic myotomy (POEM) is a safe and effective procedure for patients with achalasia [1]. Mucosal perforation is an inadvertent complication that is difficult or impossible to treat with standard clips [2]. Over-the-scope clips, endoluminal suturing devices, and fully covered stents have been used successfully [3] [4]. Cyanoacrylate is used as a sealant because of its rapid solidification rate [5]. We report on three patients who were treated successfully with cyanoacrylate following failure of standard closure.
GW27-e0063 Application of optical coherent tomography to evaluate the stability of atherosclerotic plaque in macrophages regulated by microRNA let-7b
Authors: Xianglan Liu, Yong Sun, Jian Wu, Jinwei Tian, Yang Zheng, Pei Wang, Min Yu, Shengnan Zhang, Meiqi Wang, Han Dong, Bo Yu
Journal: Journal of the American College of Cardiology (2016)
Can safety-netting improve cancer detection in patients with vague symptoms?
Authors: Brian D Nicholson, David Mant, Clare Bankhead
Journal: BMJ (2016)

#### What you need to know

Patients present daily about symptoms that could represent a new diagnosis of cancer.1 Some will present with easily recognised high risk symptoms such as dysphagia (5% likelihood of cancer if age >55 years), postmenopausal bleeding (4% likelihood if age >55 years), or haemoptysis (2% likelihood if age >40 years). But most will have vague or non-specific symptoms such as cough, fatigue, or abdominal pain.2 3 4 As these symptoms are shared with benign, chronic, or self limiting conditions, the likelihood of cancer is low (mostly under 0.5%).1 The clinical consequence is that diagnosis of cancers with vague symptoms tend to be delayed: for example, about half of patients in England with multiple myeloma have to consult three or more times before referral,5 and over a third present to hospital as emergencies.6 Depending on the cancer site, reducing diagnostic delay can lead to improved survival, earlier stage at diagnosis, and improved quality of life.7

The answer to this diagnostic problem is not to investigate every low risk symptom at first consultation.8 Doctors have a responsibility to avoid causing unnecessary alarm and wasting scarce resources through over-investigation, which may result in harm to the patient. Teasing out serious disease by following up patients over time, with planned sequential investigation, is usually the best approach for …
TCT-45 Optical Coherence Tomography Assessment of Incidence, Morphological Characteristics, and Spontaneous Healing Course of Edge Dissections Following Percutaneous Coronary Intervention with Stent Implantation in Patients with Non-ST segment Elevation Myocardial Infarction
Authors: Lisbeth Antonsen, Per Thayssen, Henrik S. Hansen, Anders Junker, Karsten T. Veien, Knud N. Hansen, Mikkel Hougaard, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2015)
F VIII Inhibitors in Haemophilia A Patients after Continuous Infusion of Factor VIII Concentrates.
Authors: Ch. von Auer, J. Oldenburg, M. von Depka, C. Escuriola-Ettinghausen, W. Kreuz, K. Kurnik, H. Lenk, M. Varvenne, I. Scharrer
Journal: Blood (2004)
TCT-38 Long-term Clinical Outcome Of Resting Pd/Pa Versus FFR-guided Deferral Of Revascularization
Authors: Gilbert Wijntjens, Mauro Echavarria-Pinto, Tim P. van de Hoef, Martijn A. van Lavieren, M. Meuwissen, Karel T. Koch, Michiel Voskuil, Robbert J. de Winter, Jan G. Tijssen, Jan Piek
Journal: Journal of the American College of Cardiology (2015)
Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol
Authors: Ester Mejstrikova, Julie Irving, Leonid Karawajew, Marian Case, Jenny Jesson, Vaskar Saha, Nicholas Goulden, Jeremy Hancock, Arend Stackelberg, Sarah Lawson, Michael Dworzak, Renate Panzer-Grumayer, Barbara Buldini, Lisa Eyre, Giuseppe Basso, Maddalena Paganin, Jan Trka, Daniela Kužílková, Jan Stary, Lucie Sramkova, Ondrej Hrusak, Cornelia Eckert
Journal: Blood (2015)
TCT-519 Feasibility and performance of everolimus-eluting bioresorbable vascular scaffolds (BVS) in long lesions (&gt;25 mm): all-comers absorb registry with mid-term follow-up
Authors: Santiago J. Camacho Freire, Jessica Roa-Garrido, Rosa M. Cardenal, Antonio Gomez Menchero, Javier Leon Jimenez, Francisco J. Landero Garcia, Prudencia Gomez Fernandez, Jose F. Diaz Fernandez
Journal: Journal of the American College of Cardiology (2015)
The Choices on Health Reform in the US Presidential and Congressional Elections
Authors: John E. McDonough, David K. Jones
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Adjuvant radiation therapy in women with stage III node-positive uterine cancer
Authors: S. Schmid, I. Hsu, J. M. Hu, C. B. Powell, L. Chen, K. Osann, D. S. Kapp, J. K. Chan
Journal: Journal of Clinical Oncology (2008)

5543 Background: To determine if adjuvant radiotherapy improves the survival of women with stage III node-positive uterine cancer. Methods: We retrospectively identified surgically staged patients with stage III uterine cancer from the Surveillance Epidemiology and End Results (SEER) database of the US National Cancer Institute from 1988 to 2001. Data were analyzed using Kaplan-Meier and logistic regression analyses. Results: Of 943 patients, the median age of the cohort was 64 years (range 28–93). 82.1%, 8.6%, and 6.8% were White, Black, and Asian. All patients were treated surgically including a lymphadenectomy and was found to have node-positive stage IIIC disease. The median number of removed nodes was 11 (range 1–90). 54.9% had a single positive node and 45.1% had 2–5 positive nodes. Endometrioid, papillary serous, sarcomas and clear cell comprised of 69.7%, 16.3%, 9.9% and 4.1% of histologies. 67.3% of the women underwent adjuvant radiotherapy, 30.8% did not receive any radiation treatment and 2% unknown. Women who received adjuvant radiotherapy had a 5-year disease-specific survival of 67.9%, compared to 53.4% in those without radiotherapy (p<0.001). Of those with a single positive node, adjuvant radiotherapy improved the 5-year disease-specific survival from 53.9% to 74.3% (p<0.001). However, radiotherapy did not improve the survival in those with 2–5 positive nodes (59.7% versus 52.7%, p=0.092). Moreover, radiation treatment improved the survival of those single-node positive patients with adenocarcinoma (80.7% vs. 63.3% p=0.012) and clear cell tumor (67.2% vs. 35% p=0.015) but not in papillary serous (54.8% vs. 45.8% p=0.619), and sarcomas (44.1% vs. 40.4% p=0.374). In the multivariate analysis, older age, non-endometrioid histology remained as a significant independent prognostic factor for worsened survival. Conclusions: Our data suggest that adjuvant radiotherapy may provide a survival benefit in women with single-positive node endometrioid uterine cancers. After adjusting for other clinico-pathologic variables, adjuvant radiotherapy was not an independent prognostic factor. No significant financial relationships to disclose.
The Results of the Russian Registry of Primary Immune Thrombocytopenia (ITP) in Adults
Authors: Igor Lisukov, Alexey Maschan, Anastasia Shamardina, Tatyana Chagorova, Igor Davydkin, Tatyana Sycheva, Tamara Zagoskina, Elena Karyagina, Galina Salogub, Marina Savinova, Tatyana Schelekhova, Lidiya Kovaleva, Tatyana Schneider, Anna Unzhekova, Elena Kuznetsova, Yuriy Schatochin, Maria Ivanova, Elena Vinogradova, Kamil Kaplanov, Inna Markova, Olimpiada Kanjukova, Kudrat Abdulkadyrov, Julia Sedlova, Svetlana Osynikhina, Nina Tsvetaeva, Elena Volodicheva, Aryslan Akhmadeev, Michael A Maschan, Alexandr Kulagin, Alexander Rumyantsev, Boris V Afanasyev
Journal: Blood (2015)
Association of Helicobacter Pylori Infection with Iron Deficiency in Asians and Pacific Islanders but not in Caucasians, African Americans, or Hispanics
Authors: Gordon D. McLaren, Joseph A. Murray, Stela McLachlan, Paul C. Adams, John H. Eckfeldt, Chris D. Vulpe, Victor R. Gordeuk, Tricia Brantner, Catherine Leiendecker-Foster, Wen-Pin Chen, Anthony A. Killeen, Ronald T. Acton, Lisa F. Barcellos, Deborah A. Nickerson, Kenneth B. Beckman, Christine E. McLaren
Journal: Blood (2015)
Evaluation of pulmonary toxicity and efficacy of a radioprotector using MRI
Authors: J. Mata, K. Sheng, P. Read, K. Hagspiel, K. Ruppert, C. Thomas, J. Mugler III
Journal: Journal of Clinical Oncology (2008)

18506 Background: Radiation induced pulmonary symptoms occur in 20% of patients who receive radiation treatment for cancer of the lung or breast. Presently, there is no clinical test available to predict symptomatic toxicity or to assess the extent of radiation induced lung injury early after treatment. We report the use of time-resolved magnetic resonance angiography (Tr-MRA) to assess the efficacy of a radioprotector in limiting radiation toxicity in a rabbit model of stereotactic radiation therapy (SRT) pulmonary injury. Methods: 10 rabbits were used, of these 4 received different radiation doses in 3 equal fractions of 7, 9, 11 or 13 Gy within a week and were intended to determine the minimum radiation dose capable of producing detectable injury using our MRA technique. Effects were measurable by MRA at the minimum dose of 9 Gy × 3 fractions. We irradiated the remaining rabbits with 3 × 11 Gy. Four of these animals received 50mg/Kg of the radioprotector amifostine, 20 min. before each SRT dose to the right lung delivered on a TomoTherapy scanner. Tr-MRA was performed using a 1.5T clinical MR scanner at baseline, 4, 8 weeks post SRT. A 3D FLASH sequence was used with 6 slices; resolution 1.4 × 1.1 × 12mm3; TR/TE = 3.3/1.2 ms; total time = 32 sec. A 3 cc injection of a Gd chelate was delivered after 2 sec. of the start. Perfusion changes were calculated from the subtracted MIP images and correlated over the multiple time points. Results: The mean baseline areas of perfused tissue were 12±1.6 cm2 (mean±STD) for the right lung (RL) and 9±1.1 cm2 for the left lung (LL). At 4 weeks post treatment, the three control rabbits (3 × 11 Gy and no radioprotector) had mean perfused areas of 9±2.1 cm2 for the RL and 10±0.5 cm2 for the LL. At the same time point, the animals that received the same radiation dose plus the radioprotector had mean perfused areas of 12±1.2 cm2 for RL and 10±0.3 cm2 for the LL. At 8 weeks post treatment, the control rabbits had obvious perfusion defects in the irradiated zone, with mean perfused areas of 7±2.3 cm2 (RL) and 9±0.1 cm2 (LL). At this time point the animals that received the radioprotector had mean values of 10±0.8 cm2 (RL) and 9±0.6 cm2 (LL). Conclusions: Tr-MRA detected radiation induced pulmonary injury 4 weeks post treatment and was able to detect reduced early treatment toxicity as a result of a clinically used radioprotector. No significant financial relationships to disclose.
TCT-500 Comparative Study With Optical Coherence Tomography At 6 And 12 Months Between Drug-eluting Stents Of Resorbable Polymer And Drug-eluting Scaffolds With Full Bioresorbable Platform Implanted In Different Lesions Of The Same Patient.
Authors: Jose M. De la Torre Hernandez, Gerard Marti, Hipolito Gutierrez, Mario Sadaba, Nieves Gonzalo, Tamara Garcia Camarero, Felipe Hernandez, Salvatore Brugaletta, Antonio Gomez Menchero, Dae-Hyun Lee, Eduardo Pinar, Belen Cid, Iñigo Lozano, Ramon Lopez Palop, Fernando Alfonso, Felipe Navarro del Amo, Pablo Salinas, Teresa Bastante-Valiente, Jose Moreu, Jose Antonio Fernandez Diaz
Journal: Journal of the American College of Cardiology (2015)
GW27-e0613 Pulmonary vein antrum radial-liner ablation for persistent atrial fibrillation: a prospective, randomized controlled pilot study
Authors: Fei Peng, Xiaoyu Lian, Li Wang, Hexi Zhang, Lei Liu, Haiwei Miao, Jianqiang Hu, Xue Zhao, Hui Gong
Journal: Journal of the American College of Cardiology (2016)
Familial Malignant Hematological Disorders: A Systematic Assessment in 216 Consecutive Patients with Acute Leukaemia.
Authors: Laetitia Huiart, Marina Lafage, Laetitia Rabayrol, Aude Charbonnier, Philippe Bourdeleau, Daniele Sainty, Diane Coso, Marie Joelle Mozziconacci, Christine Arnoulet, Anne-Marie Stoppa, Anne Murati, Marie Pascale Lehucher-Michel, Hagay Sobol, François Esinger, Norbert Vey
Journal: Blood (2006)
Epigenetic modulation enhances vaccine efficacy
Authors: G. A. Daniels, M. Chan, D. Messmer, J. Bui, D. Carson
Journal: Journal of Clinical Oncology (2008)

14651 Background: Tumors utilize both genetic and epigenetic mechanisms during development to allow for growth of the lesion and evasion of immune elimination. A variety of immune escape mechanisms have been demonstrated in both animal models and human tumors including but not limited to down modulation of target antigens, production of immune suppressive cytokines and depletion of local nutrients. Fundamental to these and many other immune escape mechanisms is the use by the cells of epigenetic changes to adapt to this selective pressure. Thus, we hypothesized that combining epigenetic modulators may enhance immune therapy by blocking the tumor cell’s ability to adapt. Methods: C57BL/6 mice were vaccinated twice utilizing a novel TLR7 agonist (1V199) covalently coupled to whole tumor cell extracts (B16cOVA) and then challenged with melanoma tumor cells (B16cOVA). One week following challenge, groups were treated with different concentrations of the DNA methylase inhibitor 5-azacytidine and followed for survival. Results: Mice treated with low concentrations of 5-azacytidine in combination with tumor cell extract vaccination were significantly protected compared to either control, 5-azacytidine or vaccine only. Conclusion: The addition of an epigenetic modifier enhances the effectiveness of our whole cell vaccine in an experimental murine melanoma model. No significant financial relationships to disclose.
Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer
Authors: Christina K. Speirs, Todd A. DeWees, Sana Rehman, Alerson Molotievschi, Maria A. Velez, Daniel Mullen, Sandra Fergus, Marco Trovo, Jeffrey D. Bradley, Cliff G. Robinson
Journal: Journal of Thoracic Oncology (2016)